First report of fludarabine in gamma-heavy chain disease.
We describe a case of gamma-heavy chain disease presenting with lymphadenopathy, splenomegaly, lytic lesions and bone marrow infiltration. Chemotherapy with epirubicin, chlorambucil and prednisolone produced a partial remission which lasted 5 months. The patient was then treated with fludarabine. After six courses of fludarabine a good partial remission was achieved which converted to complete remission with disappearance of the monoclonal IgG3 in the ensuing 12 months without further therapy. This response has, so far, been sustained for 2 1/2 years after stopping treatment.
Agrawal
S
S
Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London.
Abboudi
Z
Z
Matutes
E
E
Catovsky
D
D
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006362:Heavy Chain Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine